Company intelligence / Profile preview

ROSE Diagnostics

Carlsbad, California, United States

Ownership: Private
Development stage: Other

Overview

First patient enrolled in clinical study as of December 2024. The verifi LUNG Test is being clinically validated to ensure real-time assessment of lung biopsy sample adequacy during procedures, aiming to reduce repeat biopsies and accelerate diagnosis. Additional pilot and pivotal studies planned for 2025.

Therapeutic areas: Oncology
Modalities: Device
Industry: Pathology

Partnerships

Coastal Pulmonary Associates Scripps Health NetworkFirestone Institute for Respiratory Health

Beyond the preview

Go deeper on ROSE Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ROSE Diagnostics.

Explore the full profile